Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
BUSINESS
Sumitomo, Roivant Ink Definitive Alliance Deal; Ex-Genentech Exec to Wield Baton
Sumitomo Dainippon Pharma and Roivant Sciences said on October 31 that they have reached a definitive agreement to form a strategic alliance, which would help the Japanese drug maker fend off an anticipated “cliff” after its flagship antipsychotic loses US…
To read the full story
Related Article
- Fueled by Roivant Deal, Sumitomo Dainippon Accelerating DX as It Looks Beyond Latuda LOE
July 9, 2021
- Sumitomo Dainippon Closes US$3 Billion Roivant Deal
January 7, 2020
- Sumitomo Dainippon to Launch Global Data Design Office, Leveraging Roivant’s Technology
November 28, 2019
- Roivant Wants to Validate Its Biz Model with Commercial Success of Sumitomo Dainippon Alliance: CEO
November 5, 2019
- To Counter Latuda Patent Cliff, Sumitomo Dainippon Poised to Buy 5 “Vants” Companies from Roivant
September 9, 2019
BUSINESS
- Astellas on Track to Hit 30% Margin Goal Early after Strong H1 Scorecards
November 5, 2026
- Nxera Inks US$1.47 Billion Deal with AbbVie for IBD Drug
November 5, 2026
- Kissei Might Revise Midterm Targets as Tavneos Faces Approval Revocation
November 5, 2026
- Boehringer, Lung Cancer Society Launch 5-Year Hernexeos Real-World Study
November 5, 2026
- ASKA Snags Japan Rights to Minghui’s TED Therapy
November 5, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…